Skip to Content

Docetaxel Non-Alcohol Formula Approval History

Docetaxel Injection, Non-Alcohol Formula is an alcohol-free formulation of docetaxel for use in the treatment of patients with breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.

The approval of a non-alcohol formula follows a warning from the U.S. Food and Drug Administration (FDA) advising patients and healthcare professionals that intravenous docetaxel formulations (Taxotere, Docefrez and generics) contain ethanol (alcohol), which may cause patients to experience intoxication or feel drunk during and after treatment.

Development History and FDA Approval Process for Docetaxel Non-Alcohol Formula

Dec 28, 2015Approval Teikoku Pharma USA, Inc. Announces FDA Approval of Docetaxel Injection, Non-Alcohol Formula

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.